The decision dated 09.11.2023 and numbered 23-53/1004-M was taken to initiate an investigation about the following undertakings to determine whether undertakings operating in the pharmaceutical sector and other sectors have violated the Act no 4054 on the Protection of Competition:

1. AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi,
2. Abdi İbrahim İlaç Sanayi ve Ticaret Anonim Şirketi,
3. AstraZeneca İlaç Sanayi ve Ticaret Limited Şirketi,
4. BASF Türk Kimya Sanayi ve Ticaret Limited Şirketi,
5. Bausch & Lomb Sağlık ve Optik Ürünleri Ticaret Anonim Şirketi,
6. Bayer Türk Kimya Sanayii Limited Şirketi,
7. GlaxoSmithKline İlaçları Sanayi ve Ticaret Anonim Şirketi,
8. İlko İlaç Sanayi ve Ticaret Anonim Şirketi,
9. Johnson and Johnson Sıhhi Malzeme Sanayi ve Ticaret Limited Şirketi,
10. Liba Laboratuarları Anonim Şirketi,
11. Menarini Sağlık ve İlaç Sanayi Ticaret Anonim Şirketi,
12. Merck İlaç Ecza ve Kimya Ticaret Anonim Şirketi,
13. Merck Sharp Dohme İlaçları Limited Şirketi,
14. Michael Page International Nem İstihdam Danışmanlığı Limited Şirketi
15. Panasonic Elektronik Satış Anonim Şirketi,
16. Pfizer PFE İlaçları Anonim Şirketi,
17. Sanofi İlaç Sanayi ve Ticaret Anonim Şirketi,
18. SIFI İlaç Anonim Şirketi,
19. World Medicine İlaç Sanayi ve Ticaret Anonim Şirketi

*Investigation decisions taken by the Competition Board are announced to the public after the decision is notified to the undertakings or associations of undertakings about which an investigation has been initiated. Those announcements are made within the framework of informing the public about the decisions of the Competition Board and cannot be interpreted to mean that the undertakings or associations of undertakings under investigation violated the Act no 4054, or they are or will be subject to penal sanctions under the Act.